BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Elektrofi, Inc., a biopharmaceutical formulation technology company focused on transforming the delivery of biologic therapies through strategic...
BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Elektrofi,Inc., a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic...
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Today Elektrofi, a biopharmaceutical formulation technology company focused on leveraging strategic partnerships to revolutionize the delivery of biologic...
Elektrofi Strengthens Leadership Team with Appointments of Greg DeFilippis as Chief Business Officer and Paulette Gangemi as Chief Human Resources Officer
Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.
BOSTON--(BUSINESS WIRE)--Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced the completion of a $40 million Series B financing round. A portion of the proceeds will be used to establish a centralized GMP manufacturing line in support of multiple upcoming clinical trials. The company will also plan to double headcount over the next 12-18 months to accelerate development across a growing pipeline of licensed programs with leading pharma and biotech.
BOSTON--(BUSINESS WIRE)--Elektrofi (ELEKTROFI, INC) & IPA (IMMUNOPRECISE ANTIBODIES LTD.) (NASDAQ: IPA) (TSXV: IPA) today announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03. This collaboration aims to generate an IND-enabling data package for the FDA for an alternatively formulated version of TATX-03, named TATX-03E, that could be easily self-administered in a non-healthcare setting. By joining forces, the parties anticipate formulating TATX-03E for stable and rapid distribution to the consumer, a drug product ideally suited to serve unmet needs for rapid deployment, field use, and higher frequency dosing for immunocompromised individuals requiring on-going access to therapies and prophylaxis.
BOSTON--(BUSINESS WIRE)--Elektrofi, a Boston-based biotechnology company focused on drug formulation and delivery innovations, today announced it has entered into a contract with the Defense Health Agency (DHA) Small Business Innovation Research (SBIR) Program within the Department of Defense (DoD) focused on exploring the company’s platform formulation technology for the delivery of prefilled, high-dose formulations for the rapid deployment of antibody treatments for COVID-19 and pandemic preparation. Elektrofi’s platform formulation technology aims to provide an alternative to current delivery methods for antibody treatments, which require intravenous administration in a healthcare setting. Under the contract with DHA SBIR, Elektrofi will use its technology to pioneer COVID-19 antibody therapies for self-administration at home, widening the potential distribution for these essential medicines.